Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

Human Psychopharmacology

Volumn 23, Issue 8, 2008, Pages 693-705

  Otmani, Sarah ^a   Demazieres A ^a   Staner, C ^a   Jacob, N ^a   Nir, T ^b   Zisapel, N ^b,c   Staner, L ^a  

^a FORENAP   (France)

^b NEURIM PHARMACEUTICALS LTD   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cognitive functions; Driving simulator; Elderly; Melatonin; Zolpidem

Indexed keywords

MELATONIN; PLACEBO; STLNOX; UNCLASSIFIED DRUG; ZOLPIDEM; HYPNOTIC SEDATIVE AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAR DRIVING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SLEEP WAKING CYCLE; SUSTAINED RELEASE FORMULATION; TASK PERFORMANCE; VOLUNTEER; ATTENTION; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; RECALL;

AGED; ATTENTION; AUTOMOBILE DRIVING; COGNITION; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; MENTAL RECALL; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; PYRIDINES;

EID: 52949138639     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.980     Document Type: Article

References (84)

1. Allain H, Bentue-Ferrer D, Tarral A, Gandon JM. 2003. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects: a randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 59(3): 179-188.
2. Atkinson G, Jones H, Edwards BJ, Waterhouse JM. 2005. Effects of daytime ingestion of melatonin on short-term athletic performance. Ergonomics 48(11-14): 1512-1522.
3. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech AJ. 1993. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances and postural sway in healthy subjects. J Clin Psychopharmacol 13(2): 100-106.
4. Berthelon C, Bocca ML, Denise P, Pottier A. 2003. Do zopiclone, zolpidem and flunitrazepam have residual effects on simulated task of collision anticipation? Psychopharmacology 17(3): 324-331.
5. Bocca ML, Le Doze F, Etard O, Pottier M, L'Hoste J, Denise P. 1999. Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology 143(4): 373-379.
6. Born J, Rasch B, Gais S. 2006. Sleep to remember. Neuroscientist 12(5): 410-424.
7. Cajochen C, Krauchi K, von Arx MA, Mori D, Graw P, Wirz-Justice A. 1996. Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neurosci Lett 207(3): 209-213.
8. Danjou P, Paty I, Fruncillo R, et al. 1999. Comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 48(3): 367-374.
9. Darcourt G, Pringuey D, Salliere D, Lavoisy J. 1999. The safety and tolerability of zolpidem - an update. J Psychopharmacol 13(1): 81-93.
10. Dollins AB, Lynch HJ, Wurtman RJ, et al. 1993. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology 112(4): 490-496.
11. Dori D, Casale G, Solerte SB, et al. 1994. Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21(1-2): 121-126.
12. Drover DR. 2004. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43(4): 227-238.
13. Dubocovich ML. 2007. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 8 (Suppl 3): 34-42.
14. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W. 1998. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 38(8): 720-726.
15. Fainstein I, Bonetto AJ, Brusco LI, Cardinali DP. 1997. Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res 58: 990-1000.
16. Fairweather DB, Kerr JS, Hindmarch I. 1992. The effects of acute and repeated dose of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin. Pharmacol 43: 597-601.
17. Ferini-Strambi L, Oldani A, Zucconi M, et al. 1995. Triazolam and melatonin effects on cardiac autonomic function during sleep. Clin Neuropharmacol 18: 405-409.
18. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. 1995. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 18(6): 425-432.
19. Gais S, Born J. 2004. Declarative memory consolidation: mechanisms acting during human sleep. Learn Mem 11: 679-685.
20. Garfinkel D, Laudon M, Nof D, Zisapel N. 1995. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346(8974): 541-544.
21. Garfinkel D, Laudon M, Zisapel N. 1997. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr 24: 223-231.
22. Garfinkel D, Zisapel N, Wainstein J, Laudon M. 1999. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 159: 2456-2460.
23. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. 2005. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331(7526): 1169-1176.
24. Graw P, Werth E, Kraüchi K, Gutzwiller F, Cajochen C, Wirz-Justice A. 2001. Early morning melatonin administration impairs psychomotor vigilance. Behav Brain Res 121: 167-172.
25. Grunstein R. 2002. Insomnia: diagnosis and management. Aust Fam Physician 31(11): 995-1000.
26. Haimov I, Laudon M, Zisapel N, et al. 1994. Sleep disorders and melatonin rhythms in elderly people. BMJ 309(6948): 167.
27. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. 1995. Melatonin replacement therapy of elderly insomniacs. Sleep 18(7): 598-603.
28. Hindmarch I, Patat A, Stanley N, Paty I, Rigney U. 2001. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol 16(2): 159-167.
29. Hindmarch I, Trick L, Ridout F. 2005. A double-blind, placebo and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 183: 133-143.
30. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. 2006. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem in healthy elderly volunteers. Br J Clin Pharmacol 62(5): 538-545.
31. Holm KJ, Goa KL. 2000. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59(4): 865-889.
32. Iguchi H, Kato KI, Ibayashi H. 1982. Age dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55: 27-29.
33. Kennaway DJ, Lushington K, Dawson D, Lack L, van den Heuvel C, Rogers N. 1999. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 27(4): 210-220.
34. Kennedy DO, Scholey AB, Wesnes KA. 2000. The dose-dependent cognitive effect of acute administration of ginkgo biloba to healthy young volunteers. Psychopharmacology 151: 416-423.
35. Laudon M, Nir I, Zisapel N. 1988. Melatonin receptors in discrete brain areas of the male rat: impact of aging on density and on circadian rhythmicity. Neuroendocrinology 48: 577-583.
36. Leger D, Laudon M, Zisapel N. 2004. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 116(2): 91-95.
37. Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. 1984. Effects of melatonin on human mood and performance. Brain Res 323(2): 201-207.
38. Martin WR, Sloan JW, Sapiro JD, Jasinski DR. 1971. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
39. Matthews CG, Klove H. 1964. Instruction Manual for the Adult Neuropsychology Test Battery. University of Wisconsin Medical School: Madison.
40. Mintzer MZ, Frey JM, Yingling JE, Griffiths RR. 1997. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 8(6-7): 561-574.
41. Mistleberger RE. 2005. Circadian regulation of sleep in mammals: role of the suprachiasmatic nucleus. Brain Res Rev 49: 429-454.
42. Monti JM, Alvarino F, Cardinali D, Savio I, Pintos A. 1999. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 28(2): 85-98.
43. Neville K, McNaughton N. 1986. Anxiolytic-like action of melatonin on acquisition but not performance of DRL. Pharmacol Biochem Behav 24(6): 1497-1502.
44. Nosjean O, Ferro M, Coge F, et al. 2000. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275(40): 31311-31317.
45. O'Neil WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. 2000. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 85: 209-215.
46. Ohayon MM. 1997. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 31: 333-346.
47. Pandi-Perumal SR, Seils LK, Kayumov L, et al. 2002. Senescence, sleep, and circadian rhythms. Ageing Res Rev 1(3): 559-604.
48. Patat A, Paty I, Hindmarch I. 2001. Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol 16(5): 369-392.
49. Paul MA, Gray G, Kenny G, Pigeau RA. 2003. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 74(12): 1263-1270.
50. Peck JS, LeGoff DB, Ahmed I, Goebert D. 2004. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry 12(4): 432-436.
51. Rauchs G, Desgranges B, Foret J, Eustache F. 2005. The relationships between memory systems and sleep stages. J Sleep Res 14(2): 123-140.
52. Rogers NL, Phan O, Kennaway DJ, Dawson D. 1998. Effect of daytime oral melatonin administration on neurobehavioral performance in humans. J Pineal Res 25(1): 47-53.
53. Rogers NL, Kennaway DJ, Dawson D. 2003. Neurobehavioural performance effects of daytime melatonin and temazepam administration. J Sleep Res 12: 207-212.
54. Rush CR, Baker RW. 2001. Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Hum Psychopharmacol 16(2): 147-157.
55. Rush C, Griffiths RR. 1996. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 16(2): 146-157.
56. Rush CR, Armstrong DL, Ali JA, Pazzaglia PJ. 1998. Benzodiazepine- receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 18(2): 154-165.
57. Siegrist C, Benedetti C, Orlando A, et al. 2001. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30(1): 34-42.
58. Staner L, Ertle S, Boeijinga P, et al. 2005. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology 181(4): 790-798.
59. Stickgold R, Walker MP. 2007. Sleep-dependent memory consolidation and reconsolidation. Sleep Med 8(4): 331-343.
60. Stone BM, Turner C, Mills SL, Nicholson AN. 2000. Hypnotic activity of melatonin. Sleep 23(5): 663-669.
61. Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, FriedrichKoch A, Steffen R. 1998. Impact of melatonin on driving performance. J Travel Med 5(1): 7-13.
62. The International Response to Helsinki VI - The WMA's Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, as adopted by the 52nd WMA General Assembly, Edinburgh, October 2000.
63. Troy SM, Lucki I, Unruh M, et al. 2000. Comparison of the effects of zaleplon, zolpidem and triazolam on memory, learning and psychomotor performance. J Clin Psychopharmacol 20(3): 328-337.
64. Unden M, Roth-Schechter B. 1996. Next day effects after nighttime treatment with zolpidem: a review. Eur J Psychiatry 11 (Suppl 1): 21S-30S.
65. Ustun T, Privett M, Lecrubier Y, et al. 1996. Form, frequency and burden of sleep problems in general health care: a report from the WHO collaborative study on psychological problems in general health care. Eur Psychiatry 11: 1087-1096.
66. Vakkuri O, Leppaluoto J, Kauppila A. 1985. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci 37(5): 489-495.
67. Vaughan G. 1993. New sensitive serum melatonin radioimmunoassay employing the Kennaway G280 antibody: Syrian hamster morning adrenergic response. J Pineal Res 15: 88-103.
68. Vermeeren A. 2004. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18(5): 297-328.
69. Vermeeren A, O'Hanlon JF, Declerck AC, Kho L. 1995. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 21: 47-64.
70. Verster JC, Volkerts ER. 2004. Effects of zolpidem and temazepam on driving ability. Sleep Med 5(6): 609-610.
71. Verster JC, Volkerts ER, Schreuder AH, et al. 2002. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 22(6): 576-583.
72. Volkerts ER, Verster JC, Van Heuckelun JHG, et al. 2000. The impact on car-driving ability of zaleplon or zolpidem after a middle of the night administration. Eur Neuropsychopharmacol 10(53): S395.
73. Waldhauser F, waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. 1984. Bioavailability of oral melatonin in humans. Neuroendocrinology 39(4): 307-313.
74. Walsh JK, Engelhardt CL. 1999. The direct economic costs of insomnia in the United States for1995. Sleep 22 (Suppl 2): S386-393.
75. Wang F, Li J, Wu C, Yang J, Xu F, Zhao Q. 2003. The GABA(A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav 74(3): 573-578.
76. Wesensten NJ, Balkin TJ, Reichardt RM, Kautz MA, Saviolakis GA, Belenky G. 2005. Daytime sleep and performance following a zolpidem and melatonin cocktail. Sleep 28(1): 93-103.
77. Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR. 1989. The effects of moclobemide on cognition. J Neural Transm Suppl 28: 91-102.
78. Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S. 2000. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol 49: 110-117.
79. Wilson BA, Cockburn J, Baddeley AD. 1985. The Rivermead Behavioural Memory Test. Thames Valley Test Company: Titchfield.
80. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestinea S, Melanc MA. 2003. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 72: 2183-2198.
81. Wurtman RJ, Zhdanova I. 1995. Improvement of sleep quality by melatonin. Lancet 346(8988): 1491.
82. Wynn VT, Arendt J. 1988. Effect of melatonin on the human electrocardiogram and simple reaction time responses. J Pineal Res 5(5): 427-4435.
83. Zhdanova I. 2005. Melatonin as a hypnotic: pro. Sleep Med Rev 9(1): 51-65.
84. Zisapel N. 1999. The use of melatonin for the treatment of insomnia. Biol Signals Recept 8(1-2): 84-89.